Cochrane · systematic review · CD012775
Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta‐analysis
Piechotta, V, Adams, A, Haque, M, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
Pain, Palliative and Supportive CareAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
36
current version
GRADE rated
32
No studies
4
Included studies
NR
No studies 4 · 11.1%Ungraded 0 · 0%Very low 5 · 13.9%Low 22 · 61.1%Moderate 2 · 5.6%High 3 · 8.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings: complete control of vomiting during the overall phase (HEC) when compared to treatment with aprepitant + granisetron
Population: adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Interventions (corticosteroids included in all regimens)a Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron | no estimate extracted | NR | No studies |
fosnetupitant + palonosetron Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron | no estimate extracted | 39 studies · 21642 participants | Moderate |
aprepitant + palonosetron Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron | no estimate extracted | 39 studies · 21642 participants | Low |
aprepitant + ramosetron Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron | no estimate extracted | 39 studies · 21642 participants | Low |
fosaprepitant + palonosetron Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron | no estimate extracted | 39 studies · 21642 participants | Low |
netupitant + palonosetron Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron | no estimate extracted | 39 studies · 21642 participants | High |
fosaprepitant + granisetron Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron | no estimate extracted | 39 studies · 21642 participants | High |
aprepitant + ondansetron Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron | no estimate extracted | 39 studies · 21642 participants | Low |
fosaprepitant + ondansetron Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron | no estimate extracted | 39 studies · 21642 participants | Low |
casopitant + ondansetron Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron | no estimate extracted | 39 studies · 21642 participants | Low |
rolapitant + granisetron Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron | no estimate extracted | 39 studies · 21642 participants | Moderate |
rolapitant + ondansetron Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron | no estimate extracted | 39 studies · 21642 participants | Low |
Summary of findings: serious adverse events (HEC) when compared to treatment with aprepitant + granisetron
Population: adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Interventions (corticosteroids included in all regimens)a Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron | no estimate extracted | NR | No studies |
aprepitant + ondansetron Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron | no estimate extracted | 23 studies · 16065 participants | Very low |
fosaprepitant + ondansetron Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron | no estimate extracted | 23 studies · 16065 participants | Low |
casopitant + ondansetron Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron | no estimate extracted | 23 studies · 16065 participants | Low |
netupitant + palonosetron Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron | no estimate extracted | 23 studies · 16065 participants | Low |
aprepitant + ramosetron Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron | no estimate extracted | 23 studies · 16065 participants | Very low |
fosaprepitant + palonosetron Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron | no estimate extracted | 23 studies · 16065 participants | Very low |
fosnetupitant + palonosetron Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron | no estimate extracted | 23 studies · 16065 participants | Very low |
fosaprepitant + granisetron Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron | no estimate extracted | 23 studies · 16065 participants | Low |
aprepitant + palonosetron Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron | no estimate extracted | 23 studies · 16065 participants | Very low |
rolapitant + granisetron Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron | no estimate extracted | 23 studies · 16065 participants | Low |
Summary of findings: complete control of vomiting during the overall phase (MEC) when compared to treatment with granisetron
Population: adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Interventions (corticosteroids included in all regimens)a Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron | no estimate extracted | NR | No studies |
aprepitant + palonosetron Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron | no estimate extracted | 22 studies · 7800 participants | Low |
netupitant + palonosetron Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron | no estimate extracted | 22 studies · 7800 participants | Low |
rolapitant + granisetron Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron | no estimate extracted | 22 studies · 7800 participants | High |
palonosetron Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron | no estimate extracted | 22 studies · 7800 participants | Low |
aprepitant + granisetron Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron | no estimate extracted | 22 studies · 7800 participants | Low |
azasetron Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron | no estimate extracted | 22 studies · 7800 participants | Low |
fosaprepitant + ondansetron Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron | no estimate extracted | 22 studies · 7800 participants | Low |
aprepitant + ondansetron Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron | no estimate extracted | 22 studies · 7800 participants | Low |
casopitant + ondansetron Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron | no estimate extracted | 22 studies · 7800 participants | Low |
ondansetron Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron | no estimate extracted | 22 studies · 7800 participants | Low |
Summary of findings: serious adverse events (MEC) when compared to treatment with granisetron
Population: adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Interventions (corticosteroids included in all regimens)a Summary of findings: serious adverse events (MEC) when vs treatment with granisetron | no estimate extracted | NR | No studies |
rolapitant + granisetron Summary of findings: serious adverse events (MEC) when vs treatment with granisetron | no estimate extracted | 1 study · 1344 participants | Low |